Summit Therapeutics Inc.

4.66 USD
+0.02 (+0.43%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Summit Therapeutics Inc. stock is up 2.42% since 30 days ago. The next earnings date is May 9, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 February’s closed higher than January. In the last 1 Unusual Options Trades, there were 1 CALL.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
09 Feb 18:48 15 Mar, 2024 5.00 CALL 1100 230

About Summit Therapeutics Inc.

Summit Therapeutics Inc. conducts clinical programs focusing on Clostridioides difficile infection (CDI) The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is based in Cambridge, Massachusetts.